BSGM צמיחת הכנסות רבעונית BioSig Technologies Inc.

The change in quarterly sales volume for Biosig Technologies (BSGM) demonstrates current dynamics, where this metric equals -100.00. Revenue growth is based on the implementation of PURE EP systems in cardiology centers and the sale of consumables. Despite FDA loyalty, internal management crises are triggering capital outflows. Meanwhile, unique real-time noise filtration provides physicians with unprecedented precision during operations.
פילוחי נתונים אנליטיים מרוכזים עבור BioSig Technologies, Inc. (BSGM)

For an investor assessing the financial stability of Biosig Technologies (BSGM), this indicator serves as a measure of cash inflow dynamics by comparing current quarter revenue with the same period last year. Analyzing the current level of quarterly revenue growth allows for an assessment of the commercial success of PURE EP system implementation, where the precision of electrophysiological signal cleaning directly converts into expanded market share and sales scaling.